Literature DB >> 19155070

Course of adherence to medication and quality of life in people with schizophrenia.

Bernd Puschner1, Matthias C Angermeyer, Morven Leese, Graham Thornicroft, Aart Schene, Martijn Kikkert, Lorenzo Burti, Michele Tansella, Thomas Becker.   

Abstract

This study examined the relationship over time of adherence to anti-psychotic medication and quality of life in people with schizophrenia, taking into account effects of mediating variables. Data on on adherence, quality of life, attitude towards medication, side effects, symptom severity, and level of functioning at baseline and 1-year follow-up were obtained from 373 participants in a multi-centre trial. Participants randomised to the intervention group were offered eight sessions of adherence therapy. Data were analysed via block recursive graphical modelling. Direct links between adherence and quality of life and effects across time were scarce and weak if present. However, indirect effects could be identified, i.e. adherence at baseline affected quality of life at follow-up via symptom severity and medication side effects. These findings underline associations between "traditional" clinical outcome parameters and quality of life. Adherence might have an impact on some of these clinical outcome dimensions, and this might indirectly affect quality of life across time. Overall, findings indicate that at present, there is no plausible explanatory model of adherence. This also has consequences for clinical practice since there is no compelling evidence on how to intervene effectively to improve adherence in people with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19155070     DOI: 10.1016/j.psychres.2007.10.011

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  9 in total

1.  Better quality of life in patients offered financial incentives for taking anti-psychotic medication: Linked to improved adherence or more money?

Authors:  Katherine Moran; Stefan Priebe
Journal:  Qual Life Res       Date:  2016-02-05       Impact factor: 4.147

2.  Characteristics associated with self-reported medication adherence in persons with psychosis referred to psychosocial rehabilitation centers.

Authors:  Hélène Verdoux; Clélia Quiles; Laura Bon; Isabelle Chéreau-Boudet; Julien Dubreucq; Emilie Legros-Lafarge; Nathalie Guillard-Bouhet; Catherine Massoubre; Julien Plasse; Nicolas Franck
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-11-10       Impact factor: 5.270

3.  Validity of subjective versus objective quality of life assessment in people with schizophrenia.

Authors:  Karen P Hayhurst; Jennifer A Massie; Graham Dunn; Shôn W Lewis; Richard J Drake
Journal:  BMC Psychiatry       Date:  2014-12-24       Impact factor: 3.630

4.  A novel standard to evaluate the impact of therapeutic agents on patient safety - The BURDEN OF THERAPY™©∗.

Authors:  Ayad K Abdulahad; Robert J Snijder; Moeen K Panni; Faysal K Riaz; Andreas J Karas
Journal:  Contemp Clin Trials Commun       Date:  2016-09-23

5.  Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia.

Authors:  Alejandra Caqueo-Urízar; Alfonso Urzúa; Patricio Mena-Chamorro; Guillaume Fond; Laurent Boyer
Journal:  Patient Prefer Adherence       Date:  2020-09-03       Impact factor: 2.711

Review 6.  Current approaches to treatments for schizophrenia spectrum disorders, part II: psychosocial interventions and patient-focused perspectives in psychiatric care.

Authors:  Wai Tong Chien; Sau Fong Leung; Frederick Kk Yeung; Wai Kit Wong
Journal:  Neuropsychiatr Dis Treat       Date:  2013-09-25       Impact factor: 2.570

Review 7.  Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia.

Authors:  Gabriel Kaplan; Julio Casoy; Jacqueline Zummo
Journal:  Patient Prefer Adherence       Date:  2013-11-13       Impact factor: 2.711

8.  Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.

Authors:  George Awad; Mariam Hassan; Antony Loebel; Jay Hsu; Andrei Pikalov; Krithika Rajagopalan
Journal:  BMC Psychiatry       Date:  2014-02-23       Impact factor: 3.630

9.  Depot Typical Antipsychotics versus Oral Atypical Antipsychotics in Relapse Rate Among Patients with Schizophrenia: A Five -Year Historical Cohort Study.

Authors:  Hamid-Reza Ahmadkhaniha; Shahab Bani-Hashem; Masoud Ahmadzad-Asl
Journal:  Iran J Psychiatry Behav Sci       Date:  2014
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.